Oxidative stress and drug resistance in cancer

Drug Resistance in Cancer Cells

Volumn , Issue , 2009, Pages 137-175

  Trachootham, Dunyaporn ^a   Zhang, Wan ^a   Huang, Peng ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Antioxidant; Apoptosis; Cancer; Cell survival; Drug resistance; Glutathione; Oxidative stress; Reactive oxygen species; Redox adaptation; Redox homeostasis; Redox based therapeutic strategies; Redox sensitive transcription factors

Indexed keywords

EID: 80052682302     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-89445-4_7     Document Type: Chapter

References (270)

1. Achanta, G., and Huang, P. 2004. Role of p53 in sensing oxidative DNA damage in response to reactive oxygen species-generating agents. Cancer Res. 64:6233-6239.
2. Achanta, G., Sasaki, R., Feng, L., Carew, J. S., Lu, W., Pelicano, H., Keating, M. J., and Huang, P. 2005. Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma. Embo J. 24:3482-3492.
3. Adams, J. 2002. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med. 8:S49-54.
4. Ahmad, S., Okine, L., Wood, R., Aljian, J., and Vistica, D. T. 1987. gamma-Glutamyl transpeptidase (gamma-GT) and maintenance of thiol pools in tumor cells resistant to alkylating agents. J Cell Physiol. 131:240-246.
5. Ali-Osman, F. 1989. Quenching of DNA cross-link precursors of chloroethylnitrosoureas and attenuation of DNA interstrand cross-linking by glutathione. Cancer Res. 49:5258-5261.
6. Angel, P., and Karin, M. 1991. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta. 1072:129-157.
7. Ariga, A., Namekawa, J., Matsumoto, N., Inoue, J., and Umezawa, K. 2002. Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J Biol Chem. 277:24625-24630.
8. Arnold, N. B., Ketterer, K., Kleeff, J., Friess, H., Buchler, M. W., and Korc, M. 2004. Thioredoxin is downstream of Smad7 in a pathway that promotes growth and suppresses cisplatin-induced apoptosis in pancreatic cancer. Cancer Res. 64:3599-3606.
9. Asumendi, A., Morales, M. C., Alvarez, A., Arechaga, J., and Perez-Yarza, G. 2002. Implication of mitochondria-derived ROS and cardiolipin peroxidation in N-(4-hydroxyphenyl) retinamideinduced apoptosis. Br J Cancer. 86:1951-1956.
10. Attardi, L. D., and Donehower, L. A. 2005. Probing p53 biological functions through the use of genetically engineered mouse models. Mutat Res. 576:4-21.
11. Azad, N., Rojanasakul, Y., and Vallyathan, V. 2008. Inflammation and lung cancer: roles of reactive oxygen/nitrogen species. J Toxicol Environ Health B Crit Rev. 11:1-15.
12. Bailey, H. H., Mulcahy, R. T., Tutsch, K. D., Arzoomanian, R. Z., Alberti, D., Tombes, M. B., Wilding, G., Pomplun, M., and Spriggs, D. R. 1994. Phase I clinical trial of intravenous Lbuthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J Clin Oncol. 12:194-205.
13. Balendiran, G. K., Dabur, R., and Fraser, D. 2004. The role of glutathione in cancer. Cell Biochem Funct. 22:343-352.
14. Barranco, S. C., Townsend, C. M., Jr., Weintraub, B., Beasley, E. G., MacLean, K. K., Shaeffer, J., Liu, N. H., and Schellenberg, K. 1990. Changes in glutathione content and resistance to anticancer agents in human stomach cancer cells induced by treatments with melphalan in vitro. Cancer Res. 50:3614-3618.
15. Bates, S. E., Regis, J. I., Robey, R. W., Zhan, Z., Scala, S., and Meadows, B. J. 1994. Chemoresistance in the clinic: overview 1994. Bull Cancer. 81 Suppl 2:55s-61s.
16. Bea, F., Hudson, F. N., Chait, A., Kavanagh, T. J., and Rosenfeld, M. E. 2003. Induction of Glutathione Synthesis in Macrophages by Oxidized Low-Density Lipoproteins Is Mediated by Consensus Antioxidant Response Elements. Circ Res. 92:386-393.
17. Bedford, P., Fichtinger-Schepman, A. M., Shellard, S. A., Walker, M. C., Masters, J. R., and Hill, B. T. 1988. Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res. 48:3019-3024.
18. Behrend, L., Henderson, G., and Zwacka, R. M. 2003. Reactive oxygen species in oncogenic transformation. Biochem Soc Trans. 31:1441-1444.
19. Benassi, B., Fanciulli, M., Fiorentino, F., Porrello, A., Chiorino, G., Loda, M., Zupi, G., and Biroccio, A. 2006. c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell. 21:509-519.
20. Benlloch, M., Mena, S., Ferrer, P., Obrador, E., Asensi, M., Pellicer, J. A., Carretero, J., Ortega, A., and Estrela, J. M. 2006. Bcl-2 and Mn-SOD antisense oligodeoxynucleotides and a glutamineenriched diet facilitate elimination of highly resistant B16 melanoma cells by tumor necrosis factor-alpha and chemotherapy. J Biol Chem. 281:69-79.
21. Bours, V., Dejardin, E., Goujon-Letawe, F., Merville, M. P., and Castronovo, V. 1994. The NFkappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines. Biochem Pharmacol. 47:145-149.
22. Bracht, K., Liebeke, M., Ritter, C. A., Grunert, R., and Bednarski, P. J. 2007. Correlations between the activities of 19 standard anticancer agents, antioxidative enzyme activities and the expression of ATP-binding cassette transporters: comparison with the National Cancer Institute data. Anticancer Drugs. 18:389-404.
23. Bragado, P., Armesilla, A., Silva, A., and Porras, A. 2007. Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation. Apoptosis. 12:1733-1742.
24. Brahimi-Horn, M. C., and Pouyssegur, J. 2007. Oxygen, a source of life and stress. FEBS Lett. 581:3582-3591.
25. Brand, M. D., and Esteves, T. C. 2005. Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3. Cell Metab. 2:85-93.
26. Brown, K. K., Eriksson, S. E., Arner, E. S., and Hampton, M. B. 2008. Mitochondrial peroxiredoxin 3 is rapidly oxidized in cells treated with isothiocyanates. Free Radic Biol Med. 45:494-502.
27. Busuttil, R. A., Garcia, A. M., Cabrera, C., Rodriguez, A., Suh, Y., Kim, W. H., Huang, T. T., and Vijg, J. 2005. Organ-specific increase in mutation accumulation and apoptosis rate in CuZnsuperoxide dismutase-deficient mice. Cancer Res. 65:11271-11275.
28. Cai, Y., Lu, J., Miao, Z., Lin, L., and Ding, J. 2007. Reactive oxygen species contribute to cell killing and P-glycoprotein downregulation by salvicine in multidrug resistant K562/A02 cells. Cancer Biol Ther. 6:1794-1799.
29. Carew, J. S., Zhou, Y., Albitar, M., Carew, J. D., Keating, M. J., and Huang, P. 2003. Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. Leukemia. 17:1437-1447.
30. Chauhan, D., Neri, P., Velankar, M., Podar, K., Hideshima, T., Fulciniti, M., Tassone, P., Raje, N., Mitsiades, C., Mitsiades, N., et al. 2007. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood. 109:1220-1227.
31. Chen, G., Hutter, K. J., and Zeller, W. J. 1995. Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells. Cell Biol Toxicol. 11:273-281.
32. Chen, Y. R., Han, J., Kori, R., Kong, A. N., and Tan, T. H. 2002. Phenylethyl isothiocyanate induces apoptotic signaling via suppressing phosphatase activity against c-Jun. N-terminal kinase. J Biol Chem. 277:39334-39342.
33. Chen, Z., Trotman, L. C., Shaffer, D., Lin, H. K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. 2005. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 436:725-730.
34. Chiera, F., Meccia, E., Degan, P., Aquilina, G., Pietraforte, D., Minetti, M., Lambeth, D., and Bignami, M. 2008. Overexpression of human NOX1 complex induces genome instability in mammalian cells. Free Radic Biol Med. 44:332-342.
35. Cho, H. Y., Reddy, S. P., and Kleeberger, S. R. 2006. Nrf2 defends the lung from oxidative stress. Antioxid Redox Signal. 8:76-87.
36. Choi, C. H., Kim, H. S., Kweon, O. S., Lee, T. B., You, H. J., Rha, H. S., Jeong, J. H., Lim, D. Y., Min, Y. D., Kim, M. S., and Chung, M. H. 2000. Reactive oxygen species-specific mechanisms of drug resistance in paraquat-resistant acute myelogenous leukemia sublines. Mol Cells. 10:38-46.
37. Choi, J., Liu, R. M., and Forman, H. J. 1997. Adaptation to oxidative stress: quinone-mediated protection of signaling in rat lung epithelial L2 cells. Biochem Pharmacol. 53:987-993.
38. Clement, M. V., Hirpara, J. L., and Pervaiz, S. 2003. Decrease in intracellular superoxide sensitizes Bcl-2-overexpressing tumor cells to receptor and drug-induced apoptosis independent of the mitochondria. Cell Death Differ. 10:1273-1285.
39. Clement, M. V., and Pervaiz, S. 2001. Intracellular superoxide and hydrogen peroxide concentrations: a critical balance that determines survival or death. Redox Rep. 6:211-214.
40. Clement, M. V., Ponton, A., and Pervaiz, S. 1998. Apoptosis induced by hydrogen peroxide is mediated by decreased superoxide anion concentration and reduction of intracellular milieu. FEBS Lett. 440:13-18.
41. Clement, M. V., and Stamenkovic, I. 1996. Superoxide anion is a natural inhibitor of FAS-mediated cell death. Embo J. 15:216-225.
42. Collins, P., Jones, C., Choudhury, S., Damelin, L., and Hodgson, H. 2005. Increased expression of uncoupling protein 2 in HepG2 cells attenuates oxidative damage and apoptosis. Liver Int. 25:880-887.
43. Craiu, A., Gaczynska, M., Akopian, T., Gramm, C. F., Fenteany, G., Goldberg, A. L., and Rock, K. L. 1997. Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome betasubunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem. 272:13437-13445.
44. Cullinan, S. B., Zhang, D., Hannink, M., Arvisais, E., Kaufman, R. J., and Diehl, J. A. 2003. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol Cell Biol. 23:7198-7209.
45. Dasmahapatra, G., Nguyen, T. K., Dent, P., and Grant, S. 2006. Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl. Leuk Res. 30:1263-1272.
46. Daubeuf, S., Leroy, P., Paolicchi, A., Pompella, A., Wellman, M., Galteau, M. M., and Visvikis, A. 2002. Enhanced resistance of HeLa cells to cisplatin by overexpression of [gamma]-glutamyltransferase. Biochemical Pharmacology. 64:207-216.
47. Derdak, Z., Mark, N. M., Beldi, G., Robson, S. C., Wands, J. R., and Baffy, G. 2008. The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells. Cancer Res. 68:2813-2819.
48. Ding, B., Chi, S. G., Kim, S. H., Kang, S., Cho, J. H., Kim, D. S., and Cho, N. H. 2007. Role of p53 in antioxidant defense of HPV-positive cervical carcinoma cells following H2O2 exposure. J Cell Sci. 120:2284-2294.
49. Efferth, T., Giaisi, M., Merling, A., Krammer, P. H., and Li-Weber, M. 2007. Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. PLoS ONE. 2:e693.
50. Elchuri, S., Oberley, T. D., Qi, W., Eisenstein, R. S., Jackson Roberts, L., Van Remmen, H., Epstein, C. J., and Huang, T. T. 2005. CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. Oncogene. 24:367-380.
51. Ellerby, L. M., Ellerby, H. M., Park, S. M., Holleran, A. L., Murphy, A. N., Fiskum, G., Kane, D. J., Testa, M. P., Kayalar, C., and Bredesen, D. E. 1996. Shift of the cellular oxidation-reduction potential in neural cells expressing Bcl-2. J Neurochem. 67:1259-1267.
52. England, K., and Cotter, T. G. 2005. Direct oxidative modifications of signalling proteins in mammalian cells and their effects on apoptosis. Redox Rep. 10:237-245.
53. Estrela, J. M., Ortega, A., and Obrador, E. 2006. Glutathione in Cancer Biology and Therapy. Crit Rev Clin Lab Sci. 43:143-181.
54. Estrov, Z., Shishodia, S., Faderl, S., Harris, D., Van, Q., Kantarjian, H. M., Talpaz, M., and Aggarwal, B. B. 2003. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood. 102:987-995.
55. Fandy, T. E., Shankar, S., and Srivastava, R. K. 2008. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells. Mol Cancer. 7:60.
56. Fantin, V. R., St-Pierre, J., and Leder, P. 2006. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 9:425-434.
57. Faraonio, R., Vergara, P., Di Marzo, D., Pierantoni, M. G., Napolitano, M., Russo, T., and Cimino, F. 2006. p53 suppresses the Nrf2-dependent transcription of antioxidant response genes. J Biol Chem. 281:39776-39784.
58. Felsher, D. W., and Bishop, J. M. 1999. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci U S A. 96:3940-3944.
59. Fischer, U., Janssen, K., and Schulze-Osthoff, K. 2007. Cutting-edge apoptosis-based therapeutics: a panacea for cancer? BioDrugs. 21:273-297.
60. Franco, R., Schoneveld, O., Georgakilas, A. G., and Panayiotidis, M. I. 2008. Oxidative stress, DNA methylation and carcinogenesis. Cancer Letters. 266:6-11.
61. Fruehauf, J. P., and Meyskens, F. L., Jr. 2007. Reactive oxygen species: a breath of life or death? Clin Cancer Res. 13:789-794.
62. Fulda, S., and Debatin, K. M. 2007. HIF-1-regulated glucose metabolism: a key to apoptosis resistance? Cell Cycle. 6:790-792.
63. Fulton, A. M., and Chong, Y. C. 1992. The role of macrophage-derived TNFa in the induction of sublethal tumor cell DNA damage. Carcinogenesis. 13:77-81.
64. Furusawa, S., Kimura, E., Kisara, S., Nakano, S., Murata, R., Tanaka, Y., Sakaguchi, S., Takayanagi, M., Takayanagi, Y., and Sasaki, K. 2001. Mechanism of resistance to oxidative stress in doxorubicin resistant cells. Biol Pharm Bull. 24:474-479.
65. Gallego, M. A., Ballot, C., Kluza, J., Hajji, N., Martoriati, A., Castera, L., Cuevas, C., Formstecher, P., Joseph, B., Kroemer, G., et al. 2008. Overcoming chemoresistance of non-small cell lung carcinoma through restoration of an AIF-dependent apoptotic pathway. Oncogene. 27:1981-1992.
66. Gariboldi, M. B., Terni, F., Ravizza, R., Meschini, S., Marra, M., Condello, M., Arancia, G., and Monti, E. 2006. The nitroxide Tempol modulates anthracycline resistance in breast cancer cells. Free Radic Biol Med. 40:1409-1418.
67. Gauss, K. A., Nelson-Overton, L. K., Siemsen, D. W., Gao, Y., De Leo, F. R., and Quinn, M. T. 2007. Role of NF-kappaB in transcriptional regulation of the phagocyte NADPH oxidase by tumor necrosis factor-alpha. J Leukoc Biol. 82:729-741.
68. Gehrt, A., Erkel, G., Anke, T., and Sterner, O. 1998. Cycloepoxydon, 1-hydroxy-2-hydroxymethyl-3-pent-1-enylbenzene and 1-hydroxy-2-hydroxymethyl-3- pent-1, 3-dienylbenzene, new inhibitors of eukaryotic signal transduction. J Antibiot (Tokyo). 51:455-463.
69. Ghezzi, P. 2005. Review: Regulation of protein function by glutathionylation. Free Radical Research. 39:573-580.
70. Giorgio, M., Migliaccio, E., Orsini, F., Paolucci, D., Moroni, M., Contursi, C., Pelliccia, G., Luzi, L., Minucci, S., Marcaccio, M., et al. 2005. Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell. 122:221-233.
71. Godwin, A. K., Meister, A., O'Dwyer, P. J., Huang, C. S., Hamilton, T. C., and Anderson, M. E. 1992. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A. 89:3070-3074.
72. Gogvadze, V., Orrenius, S., and Zhivotovsky, B. 2006. Multiple pathways of cytochrome c release from mitochondria in apoptosis. Biochim Biophys Acta. 1757:639-647.
73. Golab, J., Nowis, D., Skrzycki, M., Czeczot, H., Baranczyk-Kuzma, A., Wilczynski, G. M., Makowski, M., Mroz, P., Kozar, K., Kaminski, R., et al. 2003. Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol. A superoxide dismutase inhibitor. J Biol Chem. 278:407-414.
74. Gout, P. W., Simms, C. R., and Robertson, M. C. 2003. In vitro studies on the lymphoma growthinhibitory activity of sulfasalazine. Anticancer Drugs. 14:21-29.
75. Green, R. M., Graham, M., R. O'Donovan, M., Chipman, J. K., and J. Hodges, N. 2006. Subcellular compartmentalization of glutathione: Correlations with parameters of oxidative stress related to genotoxicity. Mutagenesis. 21:383-390.
76. Griffith, O. W., and Meister, A. 1979. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem. 254:7558-7560.
77. Haddad, J. J. 2002. Antioxidant and prooxidant mechanisms in the regulation of redox (y)-sensitive transcription factors. Cell Signal. 14:879-897.
78. Halliwell, B. 2000. A super way to kill cancer cells? Nat Med. 6:1105-1106.
79. Halliwell, B. 2007. Oxidative stress and cancer: have we moved forward? Biochem J. 401:1-11.
80. Hampton, M. B., Fadeel, B., and Orrenius, S. 1998. Redox regulation of the caspases during apoptosis. Ann N Y Acad Sci. 854:328-335.
81. Hampton, M. B., and Orrenius, S. 1997. Dual regulation of caspase activity by hydrogen peroxide: implications for apoptosis. FEBS Lett. 414:552-556.
82. Han, H., Bearss, D. J., Browne, L. W., Calaluce, R., Nagle, R. B., and Von Hoff, D. D. 2002. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res. 62:2890-2896.
83. Hanahan, D., and Weinberg, R. A. 2000. The hallmarks of cancer. Cell. 100:57-70.
84. Hancock, J. T., Desikan, R., and Neill, S. J. 2001. Does the redox status of cytochrome C act as a fail-safe mechanism in the regulation of programmed cell death? Free Radic Biol Med. 31:697-703.
85. Hannes Hentze, G. K. C. V. W. E. A. W. 1999. CD95-mediated murine hepatic apoptosis requires an intact glutathione status. Hepatology. 30:177-185.
86. Hansson, J., Lewensohn, R., Ringborg, U., and Nilsson, B. 1987. Formation and removal of DNA cross-links induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells. Cancer Res. 47:2631-2637.
87. Harbottle, A., Daly, A. K., Atherton, K., and Campbell, F. C. 2001. Role of glutathione Stransferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. Int J Cancer. 92:777-783.
88. Harper, M. E., Antoniou, A., Villalobos-Menuey, E., Russo, A., Trauger, R., Vendemelio, M., George, A., Bartholomew, R., Carlo, D., Shaikh, A., et al. 2002. Characterization of a novel metabolic strategy used by drug-resistant tumor cells. Faseb J. 16:1550-1557.
89. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. 1997. Mdm2 promotes the rapid degradation of p53. Nature. 387:296-299.
90. Hayden, M. S., and Ghosh, S. 2004. Signaling to NF-kappaB. Genes Dev. 18:2195-2224.
91. Hentze, H., Kunstle, G., Volbracht, C., Ertel, W., and Wendel, A. 1999. CD95-Mediated murine hepatic apoptosis requires an intact glutathione status. Hepatology. 30:177-185.
92. Holmes-McNary, M., and Baldwin, A. S., Jr. 2000. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res. 60:3477-3483.
93. Horn, H. F., and Vousden, K. H. 2007. Coping with stress: multiple ways to activate p53. Oncogene. 26:1306-1316.
94. Hoshida, Y., Moriyama, M., Otsuka, M., Kato, N., Taniguchi, H., Shiratori, Y., Seki, N., and Omata, M. 2007. Gene expressions associated with chemosensitivity in human hepatoma cells. Hepatogastroenterology. 54:489-492.
95. Hu, Y., Rosen, D. G., Zhou, Y., Feng, L., Yang, G., Liu, J., and Huang, P. 2005. Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress. J Biol Chem. 280:39485-39492.
96. Huang, P., Feng, L., Oldham, E. A., Keating, M. J., and Plunkett, W. 2000. Superoxide dismutase as a target for the selective killing of cancer cells. Nature. 407:390-395.
97. Hug, H., Strand, S., Grambihler, A., Galle, J., Hack, V., Stremmel, W., Krammer, P. H., and Galle, P. R. 1997. Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells. J Biol Chem. 272:28191-28193.
98. Indo, H. P., Davidson, M., Yen, H. C., Suenaga, S., Tomita, K., Nishii, T., Higuchi, M., Koga, Y., Ozawa, T., and Majima, H. J. 2007. Evidence of ROS generation by mitochondria in cells with impaired electron transport chain and mitochondrial DNA damage. Mitochondrion. 7:106-118.
99. Inoue, J., Gohda, J., Akiyama, T., and Semba, K. 2007. NF-kappaB activation in development and progression of cancer. Cancer Sci. 98:268-274.
100. Irani, K., Xia, Y., Zweier, J. L., Sollott, S. J., Der, C. J., Fearon, E. R., Sundaresan, M., Finkel, T., and Goldschmidt-Clermont, P. J. 1997. Mitogenic signaling mediated by oxidants in Rastransformed fibroblasts. Science. 275:1649-1652.
101. Irmak, M. B., Ince, G., Ozturk, M., and Cetin-Atalay, R. 2003. Acquired tolerance of hepatocellular carcinoma cells to selenium deficiency: a selective survival mechanism? Cancer Res. 63:6707-6715.
102. Ishii, T., Itoh, K., Takahashi, S., Sato, H., Yanagawa, T., Katoh, Y., Bannai, S., and Yamamoto, M. 2000. Transcription Factor Nrf2 Coordinately Regulates a Group of Oxidative Stress-inducible Genes in Macrophages. J Biol Chem. 275:16023-16029.
103. Ishikawa, K., Takenaga, K., Akimoto, M., Koshikawa, N., Yamaguchi, A., Imanishi, H., Nakada, K., Honma, Y., and Hayashi, J. 2008. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science. 320:661-664.
104. Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D., and Yamamoto, M. 1999. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 13:76-86.
105. Jeon, K. I., Byun, M. S., and Jue, D. M. 2003. Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit. Exp Mol Med. 35:61-66.
106. Kakolyris, S., Giatromanolaki, A., Koukourakis, M., Powis, G., Souglakos, J., Sivridis, E., Georgoulias, V., Gatter, K. C., and Harris, A. L. 2001. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res. 7:3087-3091.
107. Kalinina, E. V., Chernov, N. N., Saprin, A. N., Kotova, Y. N., Andreev, Y. A., Solomka, V. S., and Scherbak, N. P. 2006. Changes in expression of genes encoding antioxidant enzymes, heme oxygenase-1, Bcl-2, and Bcl-xl and in level of reactive oxygen species in tumor cells resistant to doxorubicin. Biochemistry (Mosc). 71:1200-1206.
108. Kalinina, E. V., Chernov, N. N., Saprin, A. N., Kotova, Y. N., Gavrilova, Y. A., Chermnykh, N. S., and Shcherbak, N. P. 2007. Expression of genes for thioredoxin 1 and thioredoxin 2 in multidrug resistance ovarian carcinoma cells SKVLB. Bull Exp Biol Med. 144:301-303.
109. Kamiguti, A. S., Serrander, L., Lin, K., Harris, R. J., Cawley, J. C., Allsup, D. J., Slupsky, J. R., Krause, K. H., and Zuzel, M. 2005. Expression and activity of NOX5 in the circulating malignant B cells of hairy cell leukemia. J Immunol. 175:8424-8430.
110. Kaplowitz, N., Aw, T. Y., and Ookhtens, M. 1985. The regulation of hepatic glutathione. Annu Rev Pharmacol Toxicol. 25:715-744.
111. Karin, M., and Lin, A. 2002. NF-kappaB at the crossroads of life and death. Nat Immunol. 3:221-227.
112. Kasibhatla, S., Brunner, T., Genestier, L., Echeverri, F., Mahboubi, A., and Green, D. R. 1998. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell. 1:543-551.
113. Kasibhatla, S., Genestier, L., and Green, D. R. 1999. Regulation of fas-ligand expression during activation-induced cell death in T lymphocytes via nuclear factor kappaB. J Biol Chem. 274:987-992.
114. Katsman, A., Umezawa, K., and Bonavida, B. 2007. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent. Drug Resist Updat. 10:1-12.
115. Kawanishi, S., Hiraku, Y., Pinlaor, S., and Ma, N. 2006. Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol Chem. 387:365-372.
116. Kc, S., Carcamo, J. M., and Golde, D. W. 2006. Antioxidants prevent oxidative DNA damage and cellular transformation elicited by the over-expression of c-MYC. Mutat Res. 593:64-79.
117. Kensler, T. W., Wakabayashi, N., and Biswal, S. 2007. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol. 47:89-116.
118. Kim, G. J., Chandrasekaran, K., and F. Morgan, W. 2006a. Mitochondrial dysfunction, persistently elevated levels of reactive oxygen species and radiation-induced genomic instability: a review. 21:361-367.
119. Kim, H. J., Chae, H. Z., Kim, Y. J., Kim, Y. H., Hwangs, T. S., Park, E. M., and Park, Y. M. 2003. Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell Biol Toxicol. 19:285-298.
120. Kim, H. S., Oh, J. M., Jin, D. H., Yang, K. H., and Moon, E. Y. 2008. Paclitaxel induces vascular endothelial growth factor expression through reactive oxygen species production. Pharmacology. 81:317-324.
121. Kim, J. H., Bogner, P. N., Ramnath, N., Park, Y., Yu, J., and Park, Y. M. 2007. Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer. Clin Cancer Res. 13:3875-3882.
122. Kim, J. W., Tchernyshyov, I., Semenza, G. L., and Dang, C. V. 2006b. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 3:177-185.
123. Kim, S. J., Miyoshi, Y., Taguchi, T., Tamaki, Y., Nakamura, H., Yodoi, J., Kato, K., and Noguchi, S. 2005. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin Cancer Res. 11:8425-8430.
124. Kim, Y.-M., Talanian, R. V., and Billiar, T. R. 1997. Nitric Oxide Inhibits Apoptosis by Preventing Increases in Caspase-3-like Activity via Two Distinct Mechanisms. J Biol Chem. 272:31138-31148.
125. Kinnula, V. L., and Crapo, J. D. 2004. Superoxide dismutases in malignant cells and human tumors. Free Radic Biol Med. 36:718-744.
126. Kissil, J. L., Walmsley, M. J., Hanlon, L., Haigis, K. M., Bender Kim, C. F., Sweet-Cordero, A., Eckman, M. S., Tuveson, D. A., Capobianco, A. J., Tybulewicz, V. L., and Jacks, T. 2007. Requirement for Rac1 in a K-ras Induced Lung Cancer in the Mouse. Cancer Res. 67:8089-8094.
127. Kobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., and Yamamoto, M. 2004. Oxidative Stress Sensor Keap1 Functions as an Adaptor for Cul3-Based E3 Ligase To Regulate Proteasomal Degradation of Nrf2. Mol Cell Biol. 24:7130-7139.
128. Kobayashi, D., Watanabe, N., Yamauchi, N., Tsuji, N., Sato, T., and Niitsu, Y. 1997. Endogenous tumor necrosis factor as a predictor of doxorubicin sensitivity in leukemic patients. Blood. 89:2472-2479.
129. Kobayashi, M., and Yamamoto, M. 2005. MolecularMechanisms Activating the Nrf2-Keap1 Pathway of Antioxidant Gene Regulation. Antioxid Redox Signal. 7:385-394.
130. Kobayashi, M., and Yamamoto, M. 2006. Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Advances in Enzyme Regulation. 46:113-140.
131. Kong, Q., Beel, J. A., and Lillehei, K. O. 2000. A threshold concept for cancer therapy. Med Hypotheses. 55:29-35.
132. Kong, Q., and Lillehei, K. O. 1998. Antioxidant inhibitors for cancer therapy. Med Hypotheses. 51:405-409.
133. Kopnin, P. B., Agapova, L. S., Kopnin, B. P., and Chumakov, P. M. 2007. Repression of sestrin family genes contributes to oncogenic Ras-induced reactive oxygen species up-regulation and genetic instability. Cancer Res. 67:4671-4678.
134. Kotlo, K. U., Yehiely, F., Efimova, E., Harasty, H., Hesabi, B., Shchors, K., Einat, P., Rozen, A., Berent, E., and Deiss, L. P. 2003. Nrf2 is an inhibitor of the Fas pathway as identified by Achilles' Heel Method, a new function-based approach to gene identification in human cells. Oncogene. 22:797-806.
135. Kubbutat, M. H., Jones, S. N., and Vousden, K. H. 1997. Regulation of p53 stability by Mdm2. Nature. 387:299-303.
136. Kumar, B., Koul, S., Khandrika, L., Meacham, R. B., and Koul, H. K. 2008. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res. 68:1777-1785.
137. Kundu, N., Zhang, S., and Fulton, A. M. 1995. Sublethal oxidative stress inhibits tumor cell adhesion and enhances experimental metastasis of murine mammary carcinoma. Clin Exp Metastasis. 13:16-22.
138. Kuninaka, S., Ichinose, Y., Koja, K., and Toh, Y. 2000. Suppression of manganese superoxide dismutase augments sensitivity to radiation, hyperthermia and doxorubicin in colon cancer cell lines by inducing apoptosis. Br J Cancer. 83:928-934.
139. Kwak, M. K., Wakabayashi, N., Itoh, K., Motohashi, H., Yamamoto, M., and Kensler, T. W. 2003. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J Biol Chem. 278:8135-8145.
140. Lai, G. M., Ozols, R. F., Young, R. C., and Hamilton, T. C. 1989. Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. J Natl Cancer Inst. 81:535-539.
141. Lee, S. R., Kwon, K. S., Kim, S. R., and Rhee, S. G. 1998. Reversible inactivation of proteintyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor. J Biol Chem. 273:15366-15372.
142. Lee, S. R., Yang, K. S., Kwon, J., Lee, C., Jeong, W., and Rhee, S. G. 2002. Reversible inactivation of the tumor suppressor PTEN by H2O2. J Biol Chem. 277:20336-20342.
143. Lertratanangkoon, K., Savaraj, N., Scimeca, J. M., and Thomas, M. L. 1997. Glutathione depletioninduced thymidylate insufficiency for DNA repair synthesis. Biochem Biophys Res Commun. 234:470-475.
144. Li, X., Schuler, M. A., and Berenbaum, M. R. 2007. Molecular mechanisms of metabolic resistance to synthetic and natural xenobiotics. Annu Rev Entomol. 52:231-253.
145. Lightcap, E. S., McCormack, T. A., Pien, C. S., Chau, V., Adams, J., and Elliott, P. J. 2000. Proteasome inhibition measurements: clinical application. Clin Chem. 46:673-683.
146. Limoli, C. L., Giedzinski, E., Morgan, W. F., Swarts, S. G., Jones, G. D., and Hyun, W. 2003. Persistent oxidative stress in chromosomally unstable cells. Cancer Res. 63:3107-3111.
147. Lin, K. I., Pasinelli, P., Brown, R. H., Hardwick, J. M., and Ratan, R. R. 1999. Decreased intracellular superoxide levels activate Sindbis virus-induced apoptosis. J Biol Chem. 274:13650-13655.
148. Lincoln, D. T., Ali Emadi, E. M., Tonissen, K. F., and Clarke, F. M. 2003. The thioredoxinthioredoxin reductase system: over-expression in human cancer. Anticancer Res. 23:2425-2433.
149. Ling, Y. H., Liebes, L., Zou, Y., and Perez-Soler, R. 2003. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem. 278:33714-33723.
150. Lo, M., Wang, Y. Z., and Gout, P. W. 2008. The x (c) - cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol. 215:593-602.
151. Lu, H., Forbes, R. A., and Verma, A. 2002. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem. 277:23111-23115.
152. Lu, Y. P., Lou, Y. R., Yen, P., Newmark, H. L., Mirochnitchenko, O. I., Inouye, M., and Huang, M. T. 1997. Enhanced skin carcinogenesis in transgenic mice with high expression of glutathione peroxidase or both glutathione peroxidase and superoxide dismutase. Cancer Res. 57:1468-1474.
153. Maki, C. G., Huibregtse, J. M., and Howley, P. M. 1996. In vivo ubiquitination and proteasomemediated degradation of p53 (1). Cancer Res. 56:2649-2654.
154. Marzano, C., Gandin, V., Folda, A., Scutari, G., Bindoli, A., and Rigobello, M. P. 2007. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med. 42:872-881.
155. Mathas, S., Lietz, A., Janz, M., Hinz, M., Jundt, F., Scheidereit, C., Bommert, K., and Dorken, B. 2003. Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood. 102:1028-1034.
156. Matheu, A., Maraver, A., Klatt, P., Flores, I., Garcia-Cao, I., Borras, C., Flores, J. M., Vina, J., Blasco, M. A., and Serrano, M. 2007. Delayed ageing through damage protection by the Arf/p53 pathway. Nature. 448:375-379.
157. Matsuyama, S., Llopis, J., Deveraux, Q. L., Tsien, R. Y., and Reed, J. C. 2000. Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis. Nat Cell Biol. 2:318-325.
158. McGahon, A., Bissonnette, R., Schmitt, M., Cotter, K. M., Green, D. R., and Cotter, T. G. 1994. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood. 83:1179-1187.
159. Meister, A. 1988. Glutathione metabolism and its selective modification. J Biol Chem. 263:17205-17208.
160. Meuillet, E. J., Mahadevan, D., Berggren, M., Coon, A., and Powis, G. 2004. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid
161. Miyajima, A., Nakashima, J., Yoshioka, K., Tachibana, M., Tazaki, H., and Murai, M. 1997. Role of reactive oxygen species in cis- dichlorodiammineplatinum-induced cytotoxicity on bladder cancer cells. Br J Cancer. 76:206-210.
162. Morito, N., Yoh, K., Itoh, K., Hirayama, A., Koyama, A., Yamamoto, M., and Takahashi, S. 2003. Nrf2 regulates the sensitivity of death receptor signals by affecting intracellular glutathione levels. Oncogene. 22:9275-9281.
163. Motohashi, H., Katsuoka, F., Engel, J. D., and Yamamoto, M. 2004. Small Maf proteins serve as transcriptional cofactors for keratinocyte differentiation in the Keap1-Nrf2 regulatory pathway. Proc Natl Acad Sci U S A. 101:6379-6384.
164. Mu, Z. M., Yin, X. Y., and Prochownik, E. V. 2002. Pag, a putative tumor suppressor, interacts with the Myc Box II domain of c-Myc and selectively alters its biological function and target gene expression. J Biol Chem. 277:43175-43184.
165. Murawaki, Y., Tsuchiya, H., Kanbe, T., Harada, K., Yashima, K., Nozaka, K., Tanida, O., Kohno, M., Mukoyama, T., Nishimuki, E., et al. 2008. Aberrant expression of selenoproteins in the progression of colorectal cancer. Cancer Lett. 259:218-230.
166. Nagayama, S., Chen, Z. S., Kitazono, M., Takebayashi, Y., Niwa, K., Yamada, K., Tani, A., Haraguchi, M., Sumizawa, T., Furukawa, T., et al. 1998. Increased sensitivity to vincristine of MDR cells by the leukotriene D4 receptor antagonist, ONO-1078. Cancer Lett. 130:175-182.
167. Nakano, R., Oka, M., Nakamura, T., Fukuda, M., Kawabata, S., Terashi, K., Tsukamoto, K., Noguchi, Y., Soda, H., and Kohno, S. 1998. A leukotriene receptor antagonist, ONO-1078, modulates drug sensitivity and leukotriene C4 efflux in lung cancer cells expressing multidrug resistance protein. Biochem Biophys Res Commun. 251:307-312.
168. Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., and et al. 1995. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 376:37-43.
169. Nowicki, M. O., Falinski, R., Koptyra, M., Slupianek, A., Stoklosa, T., Gloc, E., Nieborowska-Skorska, M., Blasiak, J., and Skorski, T. 2004. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood. 104:3746-3753.
170. O'Brian, C. A., and Chu, F. 2005. Post-translational disulfidemodifications in cell signaling-role of inter-protein, intra-protein, S-glutathionyl, and S-cysteaminyl disulfide modifications in signal transmission. Free Radic Res. 39:471-480.
171. O'Dwyer, P. J., La Creta, F., Nash, S., Tinsley, P. W., Schilder, R., Clapper, M. L., Tew, K. D., Panting, L., Litwin, S., Comis, R. L., and et al. 1991. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res. 51:6059-6065.
172. Oberley, T. D., and Oberley, L. W. 1997. Antioxidant enzyme levels in cancer. Histol Histopathol. 12:525-535.
173. Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H., and Nakatani, Y. 1996. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 87:953-959.
174. Oh, Y. K., Lee, T. B., and Choi, C. H. 2004. Anti-oxidant adaptation in the AML cells supersensitive to hydrogen peroxide. Biochem Biophys Res Commun. 319:41-45.
175. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., and Vogelstein, B. 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 358:80-83.
176. Pahl, H. L., Krauss, B., Schulze-Osthoff, K., Decker, T., Traenckner, E. B., Vogt, M., Myers, C., Parks, T., Warring, P., Muhlbacher, A., et al. 1996. The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kappaB. J Exp Med. 183:1829-1840.
177. Pan, S., and Berk, B. C. 2007. Glutathiolation regulates tumor necrosis factor-alpha-induced caspase-3 cleavage and apoptosis: key role for glutaredoxin in the death pathway. Circ Res. 100:213-219.
178. Pani, G., Bedogni, B., Anzevino, R., Colavitti, R., Palazzotti, B., Borrello, S., and Galeotti, T. 2000. Deregulated manganese superoxide dismutase expression and resistance to oxidative injury in p53-deficient cells. Cancer Res. 60:4654-4660.
179. Patel, B. P., Rawal, U. M., Dave, T. K., Rawal, R. M., Shukla, S. N., Shah, P. M., and Patel, P. S. 2007. Lipid peroxidation, total antioxidant status, and total thiol levels predict overall survival in patients with oral squamous cell carcinoma. Integr Cancer Ther. 6:365-372.
180. Pelicano, H., Carney, D., and Huang, P. 2004. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat. 7:97-110.
181. Pelicano, H., Feng, L., Zhou, Y., Carew, J. S., Hileman, E. O., Plunkett, W., Keating, M. J., and Huang, P. 2003. Inhibition of mitochondrial respiration: a novel strategy to enhance druginduced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem. 278:37832-37839.
182. Pelicano, H., Xu, R. H., Du, M., Feng, L., Sasaki, R., Carew, J. S., Hu, Y., Ramdas, L., Hu, L., Keating, M. J., et al. 2006. Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol. 175:913-923.
183. Pervaiz, S. 2006. Pro-oxidant milieu blunts scissors: insight into tumor progression, drug resistance, and novel druggable targets. Curr Pharm Des. 12:4469-4477.
184. Pervaiz, S., Cao, J., Chao, O. S., Chin, Y. Y., and Clement, M. V. 2001. Activation of the RacGTPase inhibits apoptosis in human tumor cells. Oncogene. 20:6263-6268.
185. Pervaiz, S., and Clement, M. V. 2004. Tumor intracellular redox status and drug resistance-serendipity or a causal relationship? Curr Pharm Des. 10:1969-1977.
186. Pervaiz, S., and Clement, M. V. 2007. Superoxide anion: oncogenic reactive oxygen species? Int J Biochem Cell Biol. 39:1297-1304.
187. Pervaiz, S., Ramalingam, J. K., Hirpara, J. L., and Clement, M. V. 1999. Superoxide anion inhibits drug-induced tumor cell death. FEBS Lett. 459:343-348.
188. Pham, N. A., and Hedley, D. W. 2001. Respiratory chain-generated oxidative stress following treatment of leukemic blasts with DNA-damaging agents. Exp Cell Res. 264:345-352.
189. Pierce, J. W., Schoenleber, R., Jesmok, G., Best, J., Moore, S. A., Collins, T., and Gerritsen, M. E. 1997. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem. 272:21096-21103.
190. Pompella, A., Corti, A., Paolicchi, A., Giommarelli, C., and Zunino, F. 2007. [gamma]-Glutamyltransferase, redox regulation and cancer drug resistance. Current Opinion in Pharmacology. 7:360-366.
191. Pouyssegur, J., and Mechta-Grigoriou, F. 2006. Redox regulation of the hypoxia-inducible factor. Biol Chem. 387:1337-1346.
192. Powis, G., and Kirkpatrick, D. L. 2007. Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol. 7:392-397.
193. Radisky, D. C., Levy, D. D., Littlepage, L. E., Liu, H., Nelson, C. M., Fata, J. E., Leake, D., Godden, E. L., Albertson, D. G., Nieto, M. A., et al. 2005. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature. 436:123-127.
194. Raffel, J., Bhattacharyya, A. K., Gallegos, A., Cui, H., Einspahr, J. G., Alberts, D. S., and Powis, G. 2003. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med. 142:46-51.
195. Rahman, I., Marwick, J., and Kirkham, P. 2004. Redox modulation of chromatin remodeling: impact on histone acetylation and deacetylation, NF-kappaB and pro-inflammatory gene expression. Biochem Pharmacol. 68:1255-1267.
196. Ramanathan, B., Jan, K. Y., Chen, C. H., Hour, T. C., Yu, H. J., and Pu, Y. S. 2005. Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res. 65:8455-8460.
197. Ramanathan, R. K., Kirkpatrick, D. L., Belani, C. P., Friedland, D., Green, S. B., Chow, H. H., Cordova, C. A., Stratton, S. P., Sharlow, E. R., Baker, A., and Dragovich, T. 2007. A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors. Clin Cancer Res. 13:2109-2114.
198. Rigobello, M. P., Folda, A., Baldoin, M. C., Scutari, G., and Bindoli, A. 2005. Effect of auranofin on the mitochondrial generation of hydrogen peroxide. Role of thioredoxin reductase. Free Radic Res. 39:687-695.
199. Rivera, A., and Maxwell, S. A. 2005. The p53-induced gene-6 (proline oxidase) mediates apoptosis through a calcineurin-dependent pathway. J Biol Chem. 280:29346-29354.
200. Rosell, R., Cecere, F., Santarpia, M., Reguart, N., and Taron, M. 2006. Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol. 6:323-331.
201. Sablina, A. A., Budanov, A. V., Ilyinskaya, G. V., Agapova, L. S., Kravchenko, J. E., and Chumakov, P. M. 2005. The antioxidant function of the p53 tumor suppressor. Nat Med. 11:1306-1313.
202. Saitoh, M., Nishitoh, H., Fujii, M., Takeda, K., Tobiume, K., Sawada, Y., Kawabata, M., Miyazono, K., and Ichijo, H. 1998. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. Embo J. 17:2596-2606.
203. Salinas, A. E., and Wong, M. G. 1999. Glutathione S-transferases-a review. Curr Med Chem. 6:279-309.
204. Sanchez, M., Torres, J. V., Tormos, C., Iradi, A., Muniz, P., Espinosa, O., Salvador, A., Rodriguez-Delgado, J., Fandos, M., and Saez, G. T. 2006. Impairment of antioxidant enzymes, lipid peroxidation and 8-oxo-2'- deoxyguanosine in advanced epithelial ovarian carcinoma of a Spanish community. Cancer Lett. 233:28-35.
205. Sattler, M., Verma, S., Shrikhande, G., Byrne, C. H., Pride, Y. B., Winkler, T., Greenfield, E. A., Salgia, R., and Griffin, J. D. 2000. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem. 275:24273-24278.
206. Saydam, N., Kirb, A., Demir, O., Hazan, E., Oto, O., Saydam, O., and Guner, G. 1997. Determination of glutathione, glutathione reductase, glutathione peroxidase and glutathione S-transferase levels in human lung cancer tissues. Cancer Lett. 119:13-19.
207. Schneider, B. L., and Kulesz-Martin, M. 2004. Destructive cycles: the role of genomic instability and adaptation in carcinogenesis. Carcinogenesis. 25:2033-2044.
208. Schroder, C. P., Godwin, A. K., O'Dwyer, P. J., Tew, K. D., Hamilton, T. C., and Ozols, R. F. 1996. Glutathione and drug resistance. Cancer Invest. 14:158-168.
209. Schubbert, S., Shannon, K., and Bollag, G. 2007. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 7:295-308.
210. Sen, C. K., and Packer, L. 1996. Antioxidant and redox regulation of gene transcription. Faseb J. 10:709-720.
211. Serrano, J., Palmeira, C. M., Kuehl, D. W., and Wallace, K. B. 1999. Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration. Biochim Biophys Acta. 1411:201-205.
212. Sgambato, A., Camerini, A., Pani, G., Cangiano, R., Faraglia, B., Bianchino, G., De Bari, B., Galeotti, T., and Cittadini, A. 2003. Increased expression of cyclin E is associated with an increased resistance to doxorubicin in rat fibroblasts. Br J Cancer. 88:1956-1962.
213. Sharma, M., He, Q. Y., and Tomasz, M. 1994. Effects of glutathione on alkylation and cross-linking of DNA by mitomycin C. Isolation of a ternary glutathione-mitomycin-DNA adduct. Chem Res Toxicol. 7:401-407.
214. Shaulian, E., and Karin, M. 2002. AP-1 as a regulator of cell life and death. Nat Cell Biol. 4:E131-136.
215. Shaulian, E., Schreiber, M., Piu, F., Beeche, M., Wagner, E. F., and Karin, M. 2000. The Mammalian UV Response: c-Jun. Induction Is Required for Exit from p53-Imposed Growth Arrest. Cell. 103:897-907.
216. Shishodia, S., and Aggarwal, B. B. 2004. Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. J Biol Chem. 279:47148-47158.
217. Siedle, B., Garcia-Pineres, A. J., Murillo, R., Schulte-Monting, J., Castro, V., Rungeler, P., Klaas, C. A., Da Costa, F. B., Kisiel, W., and Merfort, I. 2004. Quantitative structure-activity rela tionship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem. 47:6042-6054.
218. Smirnov, A. S., Ruzov, A. S., Budanov, A. V., Prokhortchouk, A. V., Ivanov, A. V., and Prokhortchouk, E. B. 2001. High constitutive level of NF-kappaB is crucial for viability of adenocarcinoma cells. Cell Death Differ. 8:621-630.
219. Soussi, T. 2003. p53 mutations and resistance to chemotherapy: A stab in the back for p73. Cancer Cell. 3:303-305.
220. Spitz, D. R., Phillips, J. W., Adams, D. T., Sherman, C. M., Deen, D. F., and Li, G. C. 1993. Cellular resistance to oxidative stress is accompanied by resistance to cisplatin: the significance of increased catalase activity and total glutathione in hydrogen peroxide-resistant fibroblasts. J Cell Physiol. 156:72-79.
221. Spitz, D. R., Sim, J. E., Ridnour, L. A., Galoforo, S. S., and Lee, Y. J. 2000. Glucose deprivationinduced oxidative stress in human tumor cells. A fundamental defect in metabolism? Ann N Y Acad Sci. 899:349-362.
222. Stacy, D. R., Ely, K., Massion, P. P., Yarbrough, W. G., Hallahan, D. E., Sekhar, K. R., and Freeman, M. L. 2006. Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head Neck. 28:813-818.
223. Suh, Y. A., Arnold, R. S., Lassegue, B., Shi, J., Xu, X., Sorescu, D., Chung, A. B., Griendling, K. K., and Lambeth, J. D. 1999. Cell transformation by the superoxide-generating oxidase Mox1. Nature. 401:79-82.
224. Sullivan, R., and Graham, C. H. 2008. Chemosensitization of cancer by nitric oxide. Curr Pharm Des. 14:1113-1123.
225. Sun, J., Steenbergen, C., and Murphy, E. 2006. S-Nitrosylation: NO-Related Redox Signaling to Protect Against Oxidative Stress. Antioxid Redox Signal. 8:1693-1705.
226. Suzuki, S., Higuchi, M., Proske, R. J., Oridate, N., Hong, W. K., and Lotan, R. 1999. Implication of mitochondria-derived reactive oxygen species, cytochrome C and caspase-3 in N-(4-hydroxyphenyl) retinamide-induced apoptosis in cervical carcinoma cells. Oncogene. 18:6380-6387.
227. Swartz, H. M., and Gutierrez, P. L. 1977. Free radical increases in cancer: evidence that there is not a real increase. Science. 198:936-938.
228. Szatrowski, T. P., and Nathan, C. F. 1991. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 51:794-798.
229. Talks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., and Harris, A. L. 2000. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol. 157:411-421.
230. Teicher, B. A., Holden, S. A., Herman, T. S., Sotomayor, E. A., Khandekar, V., Rosbe, K. W., Brann, T. W., Korbut, T. T., and Frei, E., 3rd 1991. Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum (II). Int J Cancer. 47:252-260.
231. Tew, K. D. 1994. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 54:4313-4320.
232. Tew, K. D. 2007. Redox in redux: Emergent roles for glutathione S-transferase P (GSTP) in regulation of cell signaling and S-glutathionylation. Biochem Pharmacol. 73:1257-1269.
233. Tiligada, E. 2006. Chemotherapy: induction of stress responses. Endocr Relat Cancer. 13 Suppl 1:S115-124.
234. Tohyama, Y., Takano, T., and Yamamura, H. 2004. B cell responses to oxidative stress. Curr Pharm Des. 10:835-839.
235. Tomko, R. J., Jr., Bansal, P., and Lazo, J. S. 2006. Airing out an antioxidant role for the tumor suppressor p53. Mol Interv. 6:23-25, 22.
236. Tosetti, F., Vene, R., Arena, G., Morini, M., Minghelli, S., Noonan, D. M., and Albini, A. 2003. N-(4-hydroxyphenyl) retinamide inhibits retinoblastoma growth through reactive oxygen speciesmediated cell death. Mol Pharmacol. 63:565-573.
237. Townsend, D. M., and Tew, K. D. 2003. The role of glutathione-S- transferase in anti-cancer drug resistance. Oncogene. 22:7369-7375.
238. Trachootham, D., Lu, W., Ogasawara, M. A., Nilsa, R. D., and Huang, P. 2008a. Redox regulation of cell survival. Antioxid Redox Signal. 10:1343-1374.
239. Trachootham, D., Zhang, H., Zhang, W., Feng, L., Du, M., Zhou, Y., Chen, Z., Pelicano, H., Plunkett, W., Wierda, W. G., et al. 2008b. Effective Elimination of Fludarabine-Resistant CLL Cells by PEITC through a Redox-Mediated Mechanism. Blood.
240. Trachootham, D., Zhou, Y., Zhang, H., Demizu, Y., Chen, Z., Pelicano, H., Chiao, P. J., Achanta, G., Arlinghaus, R. B., Liu, J., and Huang, P. 2006. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell. 10:241-252.
241. Tsang, W. P., Chau, S. P., Kong, S. K., Fung, K. P., and Kwok, T. T. 2003. Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis. Life Sci. 73:2047-2058.
242. Tsao, S. M., Yin, M. C., and Liu, W. H. 2007. Oxidant stress and B vitamins status in patients with non-small cell lung cancer. Nutr Cancer. 59:8-13.
243. Turella, P., Cerella, C., Filomeni, G., Bullo, A., De Maria, F., Ghibelli, L., Ciriolo, M. R., Cianfriglia, M., Mattei, M., Federici, G., et al. 2005. Proapoptotic activity of new glutathione S-transferase inhibitors. Cancer Res. 65:3751-3761.
244. Turpaev, K. T. 2002. Reactive Oxygen Species and Regulation of Gene Expression. Biochemistry (Moscow). 67:281-292.
245. Vafa, O., Wade, M., Kern, S., Beeche, M., Pandita, T. K., Hampton, G. M., and Wahl, G. M. 2002. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell. 9:1031-1044.
246. Venugopal, R., and Jaiswal, A. K. 1998. Nrf2 and Nrf1 in association with Jun. proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene. 17:3145-3156.
247. Vermeulen, L., Vanden Berghe, W., and Haegeman, G. 2006. Regulation of NF-kappaB transcriptional activity. Cancer Treat Res. 130:89-102.
248. Vita, M., and Henriksson, M. 2006. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol. 16:318-330.
249. Vogel, A., Aslan, J. E., Willenbring, H., Klein, C., Finegold, M., Mount, H., Thomas, G., and Grompe, M. 2006. Sustained phosphorylation of Bid is a marker for resistance to Fas-induced apoptosis during chronic liver diseases. Gastroenterology. 130:104-119.
250. Wang, X. J., Sun, Z., Villeneuve, N. F., Zhang, S., Zhao, F., Li, Y., Chen, W., Yi, X., Zheng, W., Wondrak, G. T., et al. 2008a. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis. 29:1235-1243.
251. Wang, X. J., Sun, Z., Villeneuve, N. F., Zhang, S., Zhao, F., Li, Y., Chen, W., Yi, X., Zheng, W., Wondrak, G. T., et al. 2008b. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis.
252. Wang, Y., Saad, M., Pakunlu, R. I., Khandare, J. J., Garbuzenko, O. B., Vetcher, A. A., Soldatenkov, V. A., Pozharov, V. P., and Minko, T. 2008c. Nonviral Nanoscale-Based Delivery of Antisense Oligonucleotides Targeted to Hypoxia-Inducible Factor 1{alpha} Enhances the Efficacy of Chemotherapy in Drug-Resistant Tumor. Clin Cancer Res. 14:3607-3616.
253. Wang, Y., and Minko, T. 2004. A novel cancer therapy: combined liposomal hypoxia inducible factor 1 alpha antisense oligonucleotides and an anticancer drug. Biochem Pharmacol. 68(10):2031-2042.
254. Wek, R. C., and Cavener, D. R. 2007. Translational control and the unfolded protein response. Antioxid Redox Signal. 9:2357-2371.
255. Welsh, S., Williams, R., Kirkpatrick, L., Paine-Murrieta, G., and Powis, G. 2004. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther. 3:233-244.
256. Welsh, S. J., Bellamy, W. T., Briehl, M. M., and Powis, G. 2002. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res. 62:5089-5095.
257. Weng, Q., Wang, D., Guo, P., Fang, L., Hu, Y., He, Q., and Yang, B. 2008. Q39, a novel synthetic Quinoxaline 1, 4-Di-N-oxide compound with anti-cancer activity in hypoxia. Eur J Pharmacol. 581:262-269.
258. Wesarg, E., Hoffarth, S., Wiewrodt, R., Kroll, M., Biesterfeld, S., Huber, C., and Schuler, M. 2007. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer. 121:2387-2394.
259. Wilk, S., and Figueiredo-Pereira, M. E. 1993. Synthetic inhibitors of the multicatalytic proteinase complex (proteasome). Enzyme Protein. 47:306-313.
260. Wu, W. S. 2006. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev. 25:695-705.
261. Xia, Y. F., Ye, B. Q., Li, Y. D., Wang, J. G., He, X. J., Lin, X., Yao, X., Ma, D., Slungaard, A., Hebbel, R. P., et al. 2004. Andrographolide attenuates inflammation by inhibition of NFkappa B activation through covalent modification of reduced cysteine 62 of p50. J Immunol. 173:4207-4217.
262. Xu, C., Shen, G., Chen, C., Gelinas, C., and Kong, A. N. 2005. Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells. Oncogene. 24:4486-4495.
263. Yamakawa, H., Ito, Y., Naganawa, T., Banno, Y., Nakashima, S., Yoshimura, S., Sawada, M., Nishimura, Y., Nozawa, Y., and Sakai, N. 2000. Activation of caspase-9 and -3 during H2O2-induced apoptosis of PC12 cells independent of ceramide formation. Neurol Res. 22:556-564.
264. Yi, J., Yang, J., He, R., Gao, F., Sang, H., Tang, X., and Ye, R. D. 2004. Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res. 64:108-116.
265. Young, T. W., Mei, F. C., Yang, G., Thompson-Lanza, J. A., Liu, J., and Cheng, X. 2004. Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry. Cancer Res. 64:4577-4584.
266. Yu, C. X., Li, S., and Whorton, A. R. 2005. Redox regulation of PTEN by S-nitrosothiols. Mol Pharmacol. 68:847-854.
267. Zhang, H., Trachootham, D., Lu, W., Carew, J., Giles, F. J., Keating, M. J., Arlinghaus, R. B., and Huang, P. 2008. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia. 22:1191-1199.
268. Zhong, H., De Marzo, A. M., Laughner, E., Lim, M., Hilton, D. A., Zagzag, D., Buechler, P., Isaacs, W. B., Semenza, G. L., and Simons, J. W. 1999. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59:5830-5835.
269. Zhou, Y., Hileman, E. O., Plunkett, W., Keating, M. J., and Huang, P. 2003. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood. 101:4098-4104.
270. Zurer, I., Hofseth, L. J., Cohen, Y., Xu-Welliver, M., Hussain, S. P., Harris, C. C., and Rotter, V. 2004. The role of p53 in base excision repair following genotoxic stress. Carcinogenesis. 25:11-19.